65,437 trials
Deep Vein Thrombosis
Primary: To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT — 76.9; 65.4; 100; 96.2 % Specificity
Stroke · Hyperglycemia
Primary: Hypoglycemic Events — 7; 1; 1 participants
Rheumatoid Arthritis
Primary: Dosing Interval Between the Infliximab Infusions — 121; 205; 37 participants
Bacterial Infections · Diabetic Foot · Osteomyelitis
Primary: Number of Patients With Clinical Response of Cure Vs. Failure. — 316; 334; 92; 71 patients
Nasal Septum
Primary: Coaptation (Tissue Approximation) — 23 participants
Influenza
Primary: Laboratory-confirmed Influenza Infection — 50; 48 participants
Acne Vulgaris
Primary: Change in Inflammatory Lesion Counts Relative to Baseline — -18.0; -14.0; -19.0; -14.5 change in lesion count — p=0.7680
Human Immunodeficiency Virus Infections
Primary: Percentage of Subjects With Adverse Events of Diarrhea During the First 8 Weeks — 49.1; 54.8; 44.6; 49.7 Percentage of Subjects — p=>0.100
Neoplasms, Breast
Primary: Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment — 36; 16 Participants
HPV Infections
Primary: Measure Serious Adverse Experiences, Systemic Adverse Experiences Occurring Within 14 Days After Vaccination, and Injection-site Complaints Occurring Day 1 Through Day 5…
Coronary Heart Disease · Coronary Restenosis
Primary: Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions. — 5483; 7658.2 US dollars — p=<0.05
Plaque Psoriasis
Primary: Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to End of Treatment Based on the Overall Disease Severity (ODS) Scale — 62; 44…
Osteoarthritis Knee Pain
Primary: Weekly Change From Baseline in the 24-Hour Average Pain Rating Using an 11-Point Numerical Likert Scale Patient Diary — -0.36; -0.84; -0.95; -1.54 units on a scale…
Fibromyalgia
Primary: Visual Analog Scale for Pain — 75; 75; 75; 46 mm — p=<0.001
Breast Cancer
Primary: Objective Tumor Response — 7; 19; 19; 5 participants